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Abstract
Although activation of spinal glia has been implicated in the development of pathological pain, the
mechanisms underlying glial activation are not fully understood. One such mechanism may be
triggered by reaction to neuroactive substances released from central axons of sensory afferents. The
vanilloid receptor TRPV1, a nonselective cation channel in nociceptive sensory afferents, mediates
the release of neurotransmitters, such as glutamate and CGRP in the dorsal horn, which can
subsequently activate glia. To test the hypothesis that activation of spinal glia is mediated, at least
in part, by TRPV1, we studied the expression of markers for microglia (Ionized calcium-binding
adapter molecule 1, Iba1) and astrocytes (Glial Fibrillary Acidic Protein, GFAP) in the spinal cord
of TRPV1 knockout mice (KO) vs. wild-type mice (WT) in models of acute (intraplantar capsaicin),
inflammatory (Adjuvant-Induced Arthritis, AIA), and neuropathic pain (Partial Sciatic Nerve
Ligation, PSNL). We found that i) naïve KO mice had denser immunostaining for both Iba1 and
GFAP than naïve WT mice, ii) the immunostaining for Iba1 increased significantly in treated mice,
compared to naïve mice, 3 days after capsaicin and 7–14 days after AIA or PSNL, and was
significantly greater in WT than in KO mice 3 days after capsaicin, 7–14 days after AIA, and 7 days
after PSNL, iii) the immunostaining for GFAP increased significantly in treated mice, compared to
naïve mice, 3 days after capsaicin and 14–21 days after AIA or PSNL, and was significantly greater
in WT than in KO mice 14 days after AIA or PSNL. Our results suggest that TRPV1 plays a role in
the activation of spinal glia in mice with nociceptive, inflammatory, and neuropathic pain.
Introduction
Two major neuronal mechanisms are responsible for the pain hypersensitivity observed after
inflammatory tissue damage (inflammatory pain) and after peripheral nerve lesions or spinal
cord injury (neuropathic pain): peripheral sensitization, caused by the action of inflammatory
mediators on the peripheral terminals of sensory neurons, and central sensitization, caused by
an increase in synaptic efficacy at the level of the spinal cord, triggered by chemical, structural,
and functional plasticity in dorsal horn neurons (Sandkuhler, 2009). Recent data are beginning
to challenge the dominant “neuronal” view of central sensitization. Considerable evidence now
points to a role for glia. Indeed, neural plasticity leading to sustained hypersensitivity of
nociceptors can be triggered by signaling molecules released by activated glia (Milligan and
Watkins, 2009). During the past decade, increasing attention has been paid to neuron-glia
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interaction as a driving force for the development and maintenance of pathological pain (Scholz
and Woolf, 2007).
An important step in our understanding of the mechanisms of nociception was the cloning of
TRPV1, a non-selective cation channel that serves as a receptor for noxious heat and vanilloids
like capsaicin (Caterina et al., 1997). TRPV1 is synthesized in neurons in dorsal root ganglia
(DRG), and is transported along their peripheral axons to skin and internal organs and tissues,
including joints (Cho and Valtschanoff, 2008), and centrally to the spinal dorsal horn
(Tominaga et al., 1998). TRPV1 in sensory neurons is important for acute thermal nociception
and inflammatory hyperalgesia, and is also implicated in neuropathic pain, offering the
possibility of novel treatments of both acute pain and chronic pain disorders (Kissin, 2008;
Levine and Alessandri-Haber, 2007). Thus, silencing of TRPV1 (Christoph et al., 2006;
Christoph et al., 2007) or selective TRPV1 antagonists (Honore et al., 2005; Kanai et al.,
2005) reduced the acute pain caused by capsaicin and attenuated the hyperalgesia in models
of inflammatory and neuropathic pain (Cui et al., 2006; Szallasi et al., 2007). Providing a link
between TRPV1 and glial activation, TRPV1-mediated thermal nociception was enhanced by
inflammatory mediators that are released from glia, such as bradykinin, nerve growth factor
(NGF), and prostaglandins (Katanosaka et al., 2008; Schnizler et al., 2008).
Recently, KO mice have been used to investigate the role of TRPV1 in acute and chronic
nociception (Bolcskei et al., 2005). We applied this experimental strategy to address the
influence that the genetic deletion of TRPV1 may have on the nociceptive functions of glia.
Specifically, the goal of the present study was to ascertain whether TRPV1 may contribute to
glial activation in models of nociceptive, inflammatory, and neuropathic pain. For this, we
employed intraarticular injections of capsaicin, known to cause acute pain through specific
activation of TRPV1 on nociceptive neurons, ankle injections of complete Freund’s adjuvant
(CFA), known to cause arthralgia and arthritis (adjuvant-induced arthritis, AIA), or partial
sciatic nerve ligation (PSNL), known to cause neuropathic pain due to peripheral nerve damage.
We then investigated the changes in expression of a specific marker of microglial activation,
Iba1 (Ionized calcium-binding adapter molecule 1, Imai et al., 1996) and a specific marker for
astrocytic activation, GFAP (Glial Fibrillary Acidic Protein, Eng et al., 2000) in the dorsal horn
of TRPV1-KO, compared to wild-type mice of the same genetic background.
We hypothesized that TRPV1, expressed by dorsal horn glia and/or neurons mediates, at least
in part, the activation of glia, which in turn contributes to the induction and maintenance of
pathological pain. If confirmed, this would provide a novel mechanism for involvement of glia
in central sensitization, which underlies the hyperalgesia that often develops in the course of
inflammatory disease and peripheral nerve damage.
Materials and methods
Animals and treatments
A total of 56 male mice, ages 4–6 months and weighing 25–30 g, were used in this study. These
included 28 each of TRPV1-KO and wild-type C57BL/6 mice (Jackson Labs, Bar Harbor,
ME). All experimental procedures involving mice were carried out in compliance with the
National Research Council’s Guide for the Care and Use of Laboratory Animals, and according
to a protocol approved by the Institutional Animal Care and Use Committee at University of
North Carolina. Matching numbers of KO and WT mice divided into 4 groups. In group 1,
mice without treatment (Naïve, n=6) were sacrificed for collecting data in naïve animals. Mice
in the treatment groups were anesthetized with a mixture of ketamine and xylazine (90 mg/kg
and 10 mg/kg, i.p.); group 2 received injections of capsaicin (Cap, n=12), to model acute
nociceptive pain; in group 3, we used a model of adjuvant-induced arthritis (AIA, n=20), to
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study the effects of inflammatory pain; and group 4 received partial sciatic nerve ligature
(PSNL, n=18), to create a model of neuropathic pain.
In the Cap group, mice were injected with 20 µl of 1.5% capsaicin (Sigma, St. Louis, MO) in
a 7.5% solution of Tween 80 in saline (vehicle) into the footpad of one hind paw; the
contralateral paw was injected with the same amount of vehicle. Mice were sacrificed at 1d
(n=6) and 3d (n=6) after treatment.
For AIA, mice were injected with 10 µl of complete Freund’s adjuvant (CFA, 20 mg/ml
suspension of heat-killed Mycobacterium tuberculosis in vehicle, Difco Lab, Detroit, MI) in
each of two sites, front and back of one ankle, using a 30-gauge needle attached to a 10 µl
Hamilton syringe. The contralateral ankle was injected with the same volume of vehicle
(paraffin oil containing mannide monooleate; Freund’s incomplete adjuvant, IFA). Mice were
sacrificed at 7d (n=6), 14d (n=8), and 21d (n=6) after induction of arthritis.
For PSNL, the sciatic nerve on one side was exposed at the level of the upper thigh and chromic
collagen suture (6–0 metric) was used to create a tight ligature around approximately 40% of
the dorsal nerve fibers in the sciatic nerve (Seltzer et al., 1990). The contralateral sciatic nerve
was exposed but left intact (sham). The skin incision was repaired with Vicryl silk (5–0 metric)
suture. Mice were sacrificed at 7d (n=6), 14d (n=6), and 21d (n=6) after surgery.
Pain behavior
For assessment of pain behavior, mice were acclimated unrestrained in testing chambers, 2–3
times for 30–60 min prior to testing and nociceptive sensitivity was assessed 2 days and 1 day
before treatment (baseline), and then on days 1 and 3 after injections of capsaicin or on days
7, 14, and 21 after induction of AIA or PSNL. The latency to withdrawal from a thermal
stimulus was measured using radiant heat test (Hargreaves et al., 1988) with a Model 336 Paw/
Tail Stimulator Analgesia Meter (IITC) set at 2% idle light intensity and 40% working light
intensity. The stimulus was turned off manually upon the hindpaw withdrawal or automatically
if the 20 sec cut-off time was reached. Each mouse received 2 trials of each hindpaw with 10
min between trials and the results were averaged for analysis. Data were expressed as the
latency to withdrawal in seconds. An overall mean of post-baseline behavioral data at each
time point was calculated for each of the WT and KO groups. The behavioral testing was done
by an investigator blinded to the treatment and genotype of the mice.
Tissue processing
For tissue collection, mice under deep anesthesia with sodium pentobarbital (80 mg/kg, i.p.)
were perfused intracardially with 30 ml freshly prepared solution of 1% paraformaldehyde in
0.1 M phosphate buffer, pH 7.4 (PB), followed by 100 ml solution of 4% paraformaldehyde
in PB. Blocks including the L4 - L5 spinal cord segments were dissected out, postfixed in 4%
paraformaldehyde for 4 hours, cryoprotected in 30% sucrose in PB for 24–48 hours and
sectioned on a cryostat at 30 µm. Sections were collected in PB.
Immunohistochemistry
For immunohistochemistry, floating sections were permeabilized with 0.1% Triton X-100 in
phosphate-buffered saline (PBS; 0.01 M, pH 7.4) for 15 minutes, blocked with 5% normal
donkey serum in 0.1% Triton X-100 in PBS (NDS; Jackson Immunoresearch, West Grove,
PA) for 30 minutes, and incubated overnight with the primary antibody in NDS (goat anti-
GFAP, Santa Cruz #SC-6170, lot F2306, 1:500 or rabbit anti-Iba1, Wako #19-19741, lot
JNG4131, 1:2,000). After several rinses with PBS and incubation with 5% NDS for 30 minutes,
sections were incubated for 2 hours with appropriate secondary antibodies raised in donkey
and conjugated to Cy3 (for Iba1) or FITC (for GFAP, 1:200; Jackson Immunoresearch).
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Finally, sections were rinsed in PBS, mounted on slides, and coverslipped with Vectashield
(Vector, Burlingame, CA). Digital images were obtained with a Retiga EX cooled CCD camera
(Q-Imaging, Surrey, CA) attached to a Leitz DMR fluorescent microscope (Leitz, Wetzlar,
Germany) and saved as TIFF files. All images were captured with the camera settings held
constant; contrast and brightness were adjusted with Photoshop CS2 (Adobe Systems, San
Jose, CA); all enhancements were made uniformly across all images. As a matter of routine
control, we processed sections of spinal cord according to the above protocol, except that
primary or secondary antibodies were omitted; omission of primary or secondary antibodies
completely abolished specific staining. We also immunostained sections of all mice for TRPV1
(goat anti-TRPV1, Santa Cruz #SC-12498, lot L1406, 1:250) to verify the lack of
immunostaining in KO mice.
Data collection and statistics
Digital images were analyzed using Image J 1.38x software (NIH, Bethesda, MD). All
measurements were performed by an investigator blinded to the source material, including the
genotype of the mouse and the side (i.e., the notch identifying the right side in spinal cord
sections was blocked out of the image and images of the right dorsal horns were flipped
horizontally). For every condition and time point, images of each of the dorsal horns in each
of 4–5 sections from each animal spaced 300 µm apart were analyzed from each mouse. In
every image, the dorsal horn was manually outlined using the freehand tool, the threshold was
set just above the level of background within the outlined region, and the labeling density was
measured using the integrated density algorithm of Image J (integrated density is defined as
the sum of the values of the pixels in the selection and is equivalent to the product of area of
the selection and mean gray value within the selection, which in turn is the sum of the gray
values of all the pixels in the selection divided by the number of pixels, and is reported in
calibrated units). Data were analyzed with SPSS 11.5x (SPSS, Chicago, IL) and graphed using
Kaleidagraph (Synergy Software, Reading, PA). Differences between animal groups were
studied for significance with one-way analysis of variance (ANOVA), which assessed the
overall influence of genotype, side (left, treated or right, control), and time after each treatment
as main factors. In select cases, this was followed by a post hoc general contrast comparison
using least significant difference (LSD) test. Significance was set at p<0.05.
Results
Pain behavior
Baseline withdrawal latencies from a thermal stimulus were not significantly different between
left vs. right and between WT vs. KO mice. Mice in all treatment groups developed
hypersensitivity to thermal stimulation on the treatment side that varied according to pain
model, elapsed time after treatment, and genotype (Fig. 1). In the Cap group, WT mice had
reduced withdrawal latencies at day 1, compared to baseline, and this tendency became
significant by day 3. In contrast, KO mice did not develop hypersensitivity after capsaicin.
Surprisingly, KO mice appeared to be slightly more sensitive on the capsaicin-injected side
than on the vehicle-injected side, however, this difference was not statistically significant.
In the AIA model, CFA induced significant thermal hypersensitivity in both WT and KO mice;
withdrawal latency decreased to its lowest as early as 7 days post-injection and remained
significant until day 21. On the IFA-injected side, the withdrawal latency was not significantly
different from baseline, but was significantly longer than that on the CFA-injected side for
both genotypes. Importantly, the withdrawal latency on the CFA-injected side in KO mice was
significantly longer than that of the WT mice at day 7 and for the rest of the experiment.
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Mice in the PSNL group developed significant thermal hypersensitivity on the side of the
ligated nerve, compared to baseline, 7 days after the treatment that continued until the end of
the experiment. On the contralateral side, the withdrawal latency was not significantly different
from baseline for both genotypes. The withdrawal latency on the ligated side in KO mice was
significantly longer than that on the ligated side in WT mice at 7 days.
Immunostaining for glial markers
Immunohistochemistry for Iba1 revealed that in both WT and KO mice, the apparent intensity
of staining in the dorsal horn increased after all treatments compared to naïve mice (Fig. 2).
This increase appeared greater in WT than in KO mice and on the treated side than on the
control side, particularly at 3 days after Cap and 7 days after AIA or PSNL. The increased
overall staining seemed to reflect the increased size of labeled microglia rather than an
increased number of labeled cells: the morphology of labeled cells appeared to change with all
treatments, from small cell bodies with thin processes, characteristic of quiescent phenotype
in naïve mice, to the enlarged cell bodies with hypertrophied processes, characteristic of the
activated phenotype. The changes in cell morphology were noticeable over the entire dorsal
horn but were more pronounced in the medial half of the superficial dorsal horn, consistent
with the somatotopic representation of the paw.
A similar overall increase in staining intensity and changes in cellular morphology with
treatment was revealed by immunohistochemistry for GFAP (Fig. 3). The increased intensity
of staining, compared to levels in naïve mice, was most pronounced 3 days after capsaicin and
14 days after AIA or PSNL; the left-right difference was particularly apparent on the CFA-
injected side of the mice in the AIA group at days 14 and 21. Activated astrocyte morphology,
including enlarged cell bodies and thickened processes, was also observed with all treatments
and in the areas of the dorsal horn analogous of that for microglia.
Quantitative densitometry revealed that naïve KO mice had significantly higher overall density
of immunostaining for both Iba1 and GFAP than naïve WT mice (Fig. 4). Compared to naïve
mice, the immunostaining for Iba1 increased significantly 3 days after capsaicin and 7–14 days
after AIA or PSNL; this increase was significantly greater in WT than in KO mice at 3 days
after capsaicin, 7–14 days after AIA, and 7 days after PSNL. The immunostaining for GFAP
increased significantly 3 days after capsaicin (for both WT and KO mice) and 14–21 days after
AIA or PSNL; this increase was significantly greater in WT than in KO mice at 14 days after
AIA or PSNL.
Discussion
The main findings of this study are that i) naïve TRPV1-KO mice had greater immunostaining
for both Iba1 and GFAP than naïve WT mice, ii) the immunostaining for Iba1 increased
significantly 3 days after capsaicin and 7–14 days after AIA or PSNL and was significantly
greater in WT than in KO mice at 3 days after capsaicin, 7–14 days after AIA, and 7 days after
PSNL, and iii) the immunostaining for GFAP increased significantly 3 days after capsaicin
and 14–21 days after AIA or PSNL and was significantly greater in WT than in KO mice at
14 days after AIA or PSNL. We speculate that TRPV1 plays a role in the activation of spinal
glia in mice with acute, inflammatory, and neuropathic pain.
After surveying a variety of markers, we chose Iba1 and GFAP to quantify activated spinal
microglia and astrocytes, respectively. Iba1 is highly selectively expressed by microglia and
is specifically upregulated with microglial activation (Imai and Kohsaka, 2002; Ito et al.,
2001). It showed better correlation to pain hypersensitivity compared to the more popular
microglial marker OX-42, which makes it a better indicator of microglial reactivity in pain
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models (Obata et al., 2006). In turn, GFAP is reportedly the best marker of activated astrocytes
in adult animal preparations (Pekny and Pekna, 2004).
The observed changes in morphology of glia, from the “quiescent” phenotype in naïve mice
to the “reactive” phenotype in treated mice, were consistent with the activated state of glia
(Shapiro et al., 2009). The majority of the Iba1-positive cells in the dorsal horn that displayed
this changed morphology also expressed the activated form of p38 MAP kinase and the GFAP-
positive cells expressed the activated form of c-Jun-Activated Kinase (JNK), as revealed by a
double immunofluorescence using phospho-specific antibodies (Han, Willcockson and
Valtschanoff, unpublished observations), providing independent evidence for activation of
microglia (Ji and Suter, 2007; Tsuda et al., 2005). However, at least one recent study found no
correlation between activation and morphological changes of microglia in the adjuvant-
induced inflammatory pain model in rats using OX-42 immunohistochemistry (Lin et al.,
2007).
Our results support the notion that glial activation can be induced by C-fiber nociceptive input
from the sciatic nerve (Hathway et al., 2009) and are consistent with earlier reports implicating
glial activation in rodent models of acute and inflammatory pain (Fu et al., 2000; Sun et al.,
2007). Specifically, they corroborate recent studies suggesting that astrocytes play a role in the
initiation of acute pain and the maintenance of chronic pain, while microglial activation is
important in the early phase of chronic pain (Romero-Sandoval et al., 2008). In a rat model of
neuropathic pain, expression of mRNA for several markers of activated microglia was
upregulated 4 hours after surgery, continued to increase until day 14, and returned to normal
levels by day 28. In contrast, mRNA for GFAP did not significantly increase until day 4 and
continued to increase over the duration of the study, demonstrating that peripheral nerve injury
induces an early spinal microglial activation that precedes astrocytic activation and implicates
astrocytes in the maintenance phase of chronic pain (Tanga et al., 2004). This time course fits
the sequential activation of neurons, microglia, and astrocytes, as confirmed by the temporal
pattern of activation of MAPK (Scholz and Woolf, 2007; Zhuang et al., 2005).
Intriguingly, capsaicin induced glial activation in KO mice, albeit to a lesser degree than in
WT mice. Since this effect was not accompanied by thermal hyperalgesia, it may have been
due to a systemic effect of capsaicin that is unrelated to pain. Alternatively, TRPV1 may not
be the only sensor for capsaicin in glia. The bilateral activation of glia that we observed in WT
mice with AIA may reflect the arthritogenic potential of IFA and/or the ability of CFA, when
injected in one joint, to evoke systemic inflammation and arthritis in the contralateral joint
(Cannon et al., 1993; Szabo et al., 2005). The effect may also be central and not peripheral,
i.e. mediated by spinal cord neurons via chemical signals, possibly growth factors (Koltzenburg
et al., 1999) that may be released from activated glia.
It has been reported that TRPV1 is expressed in rat astrocytes and microglia (Doly et al.,
2004; Kim et al., 2006); depending on whether or not it is expressed by astrocytes and/or
microglia in the mouse, the effects of genetic deletion of TRPV1 on glial activation may be
direct or mediated by neurons. For example, it has been shown that TRPV1 expressed by
microglia in the rat substantia nigra contributes to microglial cell death via Ca2+ signaling and
mitochondrial damage (Kim et al., 2006) and that TRPV1 in astrocytoma cells can contribute
to apoptosis via Ca2+ influx and activation of p38 (Amantini et al., 2007). If the same
mechanisms were at play in the mouse dorsal horn, this could explain our observation that
TRPV1-KO mice have a higher density of astrocytes and microglia under normal conditions
than their wild-type littermates.
Several lines of evidence suggest that the pro-nociceptive action of cytokines is mediated, at
least in part, by TRPV1. First, long-term exposure of primary afferent neurons to the cytokine
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Tumor Necrosis Factor-alpha (TNFα) significantly increased the proportion of TRPV1-
immunoreactive neurons involved in generation of inflammatory hyperalgesia (Hensellek et
al., 2007). Moreover, both thermal hyperalgesia and the increased expression of mRNA and
protein for TRPV1 in DRG neurons were reversed by intrathecal application of neurotrophin-3,
which blocks the expression of the NGF receptor, in a model of neuropathic pain (Wilson-
Gerwing et al., 2005). Second, TRPV1-positive neurons express the β-chemokine-receptor-2
(CCR2) on their processes in the spinal dorsal horn, and intrathecal administration of the
cognate chemokine CCL2 produced thermal hyperalgesia, which was completely prevented
by an antagonist of the CCR2 (Dansereau et al., 2008), and upregulation of CCR2 may
contribute to sustained excitability of TRPV1-positive nociceptors (Jung et al., 2008). Third,
the production and release of the proinflammatory cytokine interleukin IL-6 by retinal
microglia is partially dependent on the activation of TRPV1 (Sappington and Calkins, 2008),
and the proinflammatory cytokine interleukin IL-1β can induce pain hypersensitivity by
activating TRPV1-positive nociceptors via a p38-dependent mechanism (Binshtok et al.,
2008). Providing a link to the mechanisms of arthritis, joint pathology and pain in a mouse
model of osteoarthritis were shown to be dependent on spinal IL-1β (Fiorentino et al., 2008).
Fourth, TRPV1 may also be involved in releasing inflammatory signals from immune cells
(Basu and Srivastava, 2005; Scholz and Woolf, 2007).
One mediator of neuron-glia interplay in the dorsal horn that may be critically influenced by
TRPV1 is glutamate (D'Mello and Dickenson, 2008). This is consistent with evidence that
TRPV1-expressing primary afferents are glutamatergic and release glutamate in the dorsal horn
(Hwang et al., 2004; Zhou et al., 2009). Conversely, several laboratories have reported that
increases in Ca2+ in astrocytes triggers release of glutamate that activates postsynaptic
glutamate receptors in neurons (Fiacco et al., 2009). The selective TRPV1 antagonist
SB-366791 was found to inhibit glutamatergic transmission of C-fiber input in the rat dorsal
horn following peripheral inflammation, suggesting that during inflammation, activation of
spinal TRPV1 leads to tonic synaptic release of glutamate (Lappin et al., 2006). Moreover,
capsaicin caused glutamate release from axons of small-diameter afferent fibers and
significantly decreased withdrawal latencies to thermal stimuli; these effects were inhibited by
pretreatment with capsazepine, a competitive antagonist of TRPV1 (Jin et al., 2009). We
conclude that TRPV1 is involved in activating spinal glia in mice with nociceptive and
pathological pain and that this involvement may have different underlying mechanism at
different stages during the progression of the pain state.
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Sensitivity to noxious heat of wild type mice (WT) vs. TRPV1-KO mice (KO) at baseline (time
point 0) and 1–3 days after intraplantar capsaicin (Cap), and 7–21 days after intraarticular CFA
(AIA) or partial sciatic nerve ligature (PSNL). Sensitivity on the control side was not
significantly different from baseline for all treatments (not shown for clarity). Data are plotted
as the mean ± standard error of mean, *p<0.05 for WT vs. KO.
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Immunostaining for Iba1 in naïve wild type (WT) and TRPV1-KO (KO) mice and in pain
models (the sections are from the dorsal horn of spinal segment L4 ipsilateral to the treatment:
Cap, 3 days after intraplantar capsaicin; AIA, 14 days after intraarticular CFA; PSNL, 14 days
after partial sciatic nerve ligature). Enlargements in the insets demonstrate the changes in cell
shape of microglia between naïve mice and various treatments. Scale bars, 100 µm and 20 µm
in the inset.
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Immunostaining for GFAP in naïve wild type (WT) and TRPV1-KO (KO) mice and in pain
models (the sections are from the dorsal horn of spinal segment L4 ipsilateral to the treatment:
Cap, 3 days after intraplantar capsaicin; AIA, 14 days after intraarticular CFA; PSNL, 14 days
after partial sciatic nerve ligature). Enlargements in the insets demonstrate the changes in the
cell shape of astrocytes between naïve mice and various treatments. Scale bars, 100 µm and
20 µm in the inset.
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Density (mean ± standard error of mean) of immunostaining for Iba1 and GFAP in the dorsal
horn in naïve wild-type (WT) and TRPV1-KO (KO) mice (open symbols at time point “0”)
and after intraplantar capsaicin (Cap) or vehicle (Veh), intraarticular CFA or IFA (AIA), and
partial sciatic nerve ligature (PSNL) or sham-operated mice. *p<0.05 for WT vs. KO.
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